Abstract: The present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for prevention or treatment of cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative. The N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.

Abstract: The present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for prevention or treatment of cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative. The N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.

Abstract: The present disclosure relates to a pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, including an oxyiminomethylbenzene derivative or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for prevention or treatment of cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative. The N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.

Abstract: Methods for obtaining structural data from RNA in a sample, and RNA probes for performing the same, are provided. Methods of reversibly modifying RNA is a sample, in vitro or in vivo, and reversible probes for performing the same, are provided. The RNA probes may be SHAPE probes that include aryl or heteroaryl acyl imidazoles. The RNA probes may be reversible probes that include an aryl or heteroaryl ring substituted with a hydroxyl-reactive group and an azido-containing group. Also provided are methods of comparing in vitro and in vivo RNA structural data. Also provided are methods of diagnosing a cellular proliferative disease condition, e.g., by probing HOTAIR RNA. Aspects of the invention further include compositions, e.g., probes and kits, etc., that find use in methods of the invention.

Abstract: Methods for obtaining structural data from RNA in a sample, and RNA probes for performing the same, are provided. Methods of reversibly modifying RNA is a sample, in vitro or in vivo, and reversible probes for performing the same, are provided. The RNA probes may be SHAPE probes that include aryl or heteroaryl acyl imidazoles. The RNA probes may be reversible probes that include an aryl or heteroaryl ring substituted with a hydroxyl-reactive group and an azido-containing group. Also provided are methods of comparing in vitro and in vivo RNA structural data. Also provided are methods of diagnosing a cellular proliferative disease condition, e.g., by probing HOTAIR RNA. Aspects of the invention further include compositions, e.g., probes and kits, etc., that find use in methods of the invention.

Abstract: An exhaust-downpipe of a vehicle may include a base portion connected to a top of a catalyst converter having a vertical cylinder, an inlet circularly opened in a horizontal direction, an introduction round portion extending straight along the horizontal direction from the inlet and then and curvedly bent downward toward the base portion, and branch line portions connected to both outsides above the base portion with both ways branching and drawing a circular arc from the introduction round portion.

Abstract: Presents novel hollow fiber shaped organic nanotubes that can be easily produced in a short time span and also have a broad range of utility. An N-glycoside type glycolipid represented by the general formula (1) shown below. G-NHCO—R??(1) (In the formula, G represents a saccharide radical other than a hemiacetal hydroxyl group bonded to the anomer carbon atom of the saccharide, and R represents an unsaturated hydrocarbon group containing ten to 39 carbon atoms.) This molecule self-aggregates and forms hollow fiber shaped organic nanotubes in water when this N-glycoside type glycolipid is dissolved, allowed to cool gradually and allowed to stand undisturbed at room temperature. The average external diameter of the nanotubes is from 70 nm to 500 nm and the average internal diameter (average diameter of the cavity) is from 40 nm to 300 nm.

Abstract: A gelatinizer having gel-forming capability in both organic solvents and water, is provided. The hydrogelatinizer is represented by: (where, A is a sugar residue, and R is an alkyl group).

Abstract: A gelatinizer having gel-forming capability in both organic solvents and water, is provided.